Akebia Therapeutics, Inc. (AKBA): Price and Financial Metrics

Akebia Therapeutics, Inc. (AKBA): $0.42

0.00 (1.18%)

POWR Rating

Component Grades













Add AKBA to Watchlist
Sign Up

Industry: Biotech



in industry


  • AKBA scores best on the Growth dimension, with a Growth rank ahead of 88.57% of US stocks.
  • The strongest trend for AKBA is in Growth, which has been heading up over the past 179 days.
  • AKBA ranks lowest in Sentiment; there it ranks in the 8th percentile.

AKBA Stock Summary

  • Akebia Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 82.33% of US listed stocks.
  • As for revenue growth, note that AKBA's revenue has grown -27.68% over the past 12 months; that beats the revenue growth of only 5.88% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AKBA comes in at -20.11% -- higher than that of only 18.28% of stocks in our set.
  • Stocks that are quantitatively similar to AKBA, based on their financial statements, market capitalization, and price volatility, are CYRN, OPTT, XBIO, AWRE, and CLXT.
  • Visit AKBA's SEC page to see the company's official filings. To visit the company's web site, go to www.akebia.com.

AKBA Valuation Summary

  • AKBA's price/sales ratio is 2.3; this is 39.47% lower than that of the median Healthcare stock.
  • AKBA's price/sales ratio has moved NA NA over the prior 91 months.
  • Over the past 91 months, AKBA's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for AKBA.

Stock Date P/S P/B P/E EV/EBIT
AKBA 2021-08-31 2.3 2.9 -1.7 -1.3
AKBA 2021-08-30 2.2 2.8 -1.6 -1.3
AKBA 2021-08-27 2.2 2.8 -1.7 -1.3
AKBA 2021-08-26 2.1 2.6 -1.5 -1.1
AKBA 2021-08-25 2.1 2.7 -1.6 -1.2
AKBA 2021-08-24 2.1 2.6 -1.5 -1.1

AKBA Growth Metrics

    The year over year net cashflow from operations growth rate now stands at 56.22%.
  • Its 5 year cash and equivalents growth rate is now at 165.6%.
  • Its 2 year net income to common stockholders growth rate is now at -380.35%.
AKBA's revenue has moved up $213,578,000 over the prior 70 months.

The table below shows AKBA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 213.578 -252.965 -282.84
2021-09-30 210.672 -220.939 -299.162
2021-06-30 221.904 -191.906 -299.577
2021-03-31 259.133 -91.545 -392.29
2020-12-31 295.307 -110.388 -383.457
2020-09-30 308.163 -171.741 -390.94

AKBA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AKBA has a Quality Grade of C, ranking ahead of 61.34% of graded US stocks.
  • AKBA's asset turnover comes in at 0.347 -- ranking 132nd of 682 Pharmaceutical Products stocks.
  • BPTH, ASLN, and ARDX are the stocks whose asset turnover ratios are most correlated with AKBA.

The table below shows AKBA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.347 0.186 -1.786
2021-03-31 0.385 -0.169 -2.192
2020-12-31 0.414 -0.002 -1.908
2020-09-30 0.414 0.121 -1.912
2020-06-30 0.439 0.181 -2.161
2020-03-31 0.442 0.596 -1.469

AKBA Price Target

For more insight on analysts targets of AKBA, see our AKBA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.54 Average Broker Recommendation 1.62 (Moderate Buy)

AKBA Stock Price Chart Interactive Chart >

Price chart for AKBA

AKBA Price/Volume Stats

Current price $0.42 52-week high $3.35
Prev. close $0.41 52-week low $0.30
Day low $0.40 Volume 1,723,593
Day high $0.42 Avg. volume 8,896,038
50-day MA $0.40 Dividend yield N/A
200-day MA $1.45 Market Cap 77.03M

Akebia Therapeutics, Inc. (AKBA) Company Bio

Akebia Therapeutics focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. The company was founded in 2007 and is based in Cambridge, Massachusetts.

AKBA Latest News Stream

Event/Time News Detail
Loading, please wait...

AKBA Latest Social Stream

Loading social stream, please wait...

View Full AKBA Social Stream

Latest AKBA News From Around the Web

Below are the latest news stories about Akebia Therapeutics Inc that investors may wish to consider to help them evaluate AKBA as an investment opportunity.

Akebia amends license agreement with Vifor for potential launch of kidney drug

Akebia Therapeutics (AKBA -0.8%) amended a license agreement with Vifor Pharma <> for the former's vadadustat, a potential treatment for anemia due to chronic kidney disease. Under the earlier agreement, Vifor (OTCPK:GNHAF) received an exclusive license to sell vadadustat to Fresenius Medical Care North America. With the new terms, Vifor (OTCPK:GNHAF)...

Seeking Alpha | February 22, 2022

Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and Vifor Pharma Group (Vifor Pharma), today announced that the companies have amended and restated the terms of their license agreement, pursuant to which Akebia Therapeutics, Inc. (Akebia) granted Vifor Pharma an exclusive license to sell vadadustat, Akebia's investigational oral therapeutic for the treatment of anemia due to chronic kidney disease (C

Yahoo | February 22, 2022

Akebia Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year 2021 ended December 31, 2021, on Tuesday, March 1, 2022.

Yahoo | February 9, 2022

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 129,000 shares of Akebia's common stock on January 31, 2022, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Yahoo | February 1, 2022

Top Biotech Stocks for Q1 2022

The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.

Yahoo | January 18, 2022

Read More 'AKBA' Stories Here

AKBA Price Returns

1-mo -0.45%
3-mo 25.60%
6-mo -76.67%
1-year -82.72%
3-year -91.06%
5-year -97.20%
YTD -81.42%
2021 -19.29%
2020 -55.70%
2019 14.29%
2018 -62.81%
2017 42.84%

Continue Researching AKBA

Here are a few links from around the web to help you further your research on Akebia Therapeutics Inc's stock as an investment opportunity:

Akebia Therapeutics Inc (AKBA) Stock Price | Nasdaq
Akebia Therapeutics Inc (AKBA) Stock Quote, History and News - Yahoo Finance
Akebia Therapeutics Inc (AKBA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0872 seconds.